Combination of 5-ALA and iMRI in re-resection of recurrent glioblastoma

References

• Senft C, Franz K, Blasel S, et al. Influence of iMRI-guidance on the extent of resection and survival of patients with glioblastoma multiforme. Technol Cancer Res Treat 2010;9:339–46.
   PubMed Web of Science ®Google Scholar
• Senft C, Franz K, Ulrich CT, et al. Low field intraoperative MRI-guided surgery of gliomas: a single center experience. Clin Neurol Neurosurg 2010;112:237–43.
   PubMed Web of Science ®Google Scholar
• Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006;7:392–401.
   PubMed Web of Science ®Google Scholar
• Cai LB, Li J, Lai MY, et al. Bevacizumab rescue therapy extends the survival in patients with recurrent malignant glioma. Chin J Cancer Res 2013;25:206–11.
   PubMed Web of Science ®Google Scholar
• Chaichana KL, Zadnik P, Weingart JD, et al. Multiple resections for patients with glioblastoma: prolonging survival. J Neurosurg 2013;118:812–20.
   PubMed Web of Science ®Google Scholar
• Chen C, Huang R, MacLean A, et al. Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival. J Neurooncol 2013;115:267–76.
   PubMed Web of Science ®Google Scholar
• Hundsberger T, Brügge D, Putora PM, Weder P, Weber J, Plasswilm L. Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas. J Neurooncol 2013;112:133–9.
   PubMed Web of Science ®Google Scholar
• Nieder C, Grosu AL, Molls M. A comparison of treatment results for recurrent malignant gliomas. Cancer Treat Rev 2000;26:397–409.
   PubMed Web of Science ®Google Scholar
• Sia Y, Field K, Rosenthal M, Drummond K. Socio-demographic factors and their impact on the number of resections for patients with recurrent glioblastoma. J Clin Neurosci 2013;20:1362–5.
   PubMed Web of Science ®Google Scholar
• Barbagallo GM, Jenkinson MD, Brodbelt AR. ‘Recurrent’ glioblastoma multiforme, when should we reoperate? Br J Neurosurg 2008;22:452–5.
   PubMed Web of Science ®Google Scholar
• Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. J Neurosurg 2012;117:1032–8.
   PubMed Web of Science ®Google Scholar
• Lescher S, Schniewindt S, Jurcoane A, Senft C, Hattingen E. Time window for postoperative reactive enhancement after resection of brain tumours: less than 72 hours. Neurosurg Focus 2014;37:E3.
   Google Scholar
• Nabavi A, Thurm H, Zountsas B, et al. Five-aminolevulinic acid for fluorescence-guided resection of recurrent malignant gliomas: a phase ii study. Neurosurgery 2009;65:1070–6 (discussion 1076–7).
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96.
   PubMed Web of Science ®Google Scholar
• Quick J, Gessler F, Dützmann S, et al. Benefit of tumour resection for recurrent glioblastoma. J Neurooncol 2014;117:365–72.
   PubMed Web of Science ®Google Scholar
• Senft C, Bink A, Franz K, Vatter H, Gasser T, Seifert V. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol 2011;12:997–1003.
   PubMed Web of Science ®Google Scholar
• Della Puppa A, Ciccarino P, Lombardi G, Rolma G, Cecchin D, Rossetto M. 5-aminolevulinic acid fluorescence in high grade glioma surgery: surgical outcome, intraoperative findings, and fluorescence patterns. Biomed Res Int 2014;2014:232561.
   PubMed Web of Science ®Google Scholar
• Díez Valle R, Tejada Solis S, Idoate Gastearena MA, García de Eulate R, Domínguez Echávarri P, Aristu Mendiroz J. Surgery guided by 5-aminolevulinic fluorescence in glioblastoma: volumetric analysis of extent of resection in single-center experience. J Neurooncol 2011;102:105–13.
   PubMed Web of Science ®Google Scholar
• Chaichana KL, Parker SL, Mukherjee D, Cheng JS, Gokaslan ZL, McGirt MJ. Assessment of the extent of surgical resection as a predictor of survival in patients with primary osseous spinal neoplasms. Clin Neurosurg 2011;58:117–21.
   PubMedGoogle Scholar
• Keles GE, Anderson B, Berger MS. The effect of extent of resection on time to tumour progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol 1999;52:371–9.
   PubMed Web of Science ®Google Scholar
• Helseth R, Helseth E, Johannesen TB, et al. Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme. Acta Neurol Scand 2010;122:159–67.
   PubMed Web of Science ®Google Scholar
• Stark AM, Nabavi A, Mehdorn HM, Blömer U. Glioblastoma multiforme-report of 267 cases treated at a single institution. Surg Neurol 2005;63:162–9 (discussion 169).
   PubMed Web of Science ®Google Scholar
• Weller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent glioblastoma – are we there yet? Neuro Oncol 2013;15:4–27.
   PubMed Web of Science ®Google Scholar
• Ringel F, Pape H, Sabel M, et al. Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection. Neuro Oncol 2015. [Epub ahead of print]. DOI: 10.1093/neuonc/nov145.
   PubMed Web of Science ®Google Scholar
• Suchorska B, Weller M, Tabatabai G, et al. 136 complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma results from the DIRECTOR trial. Neurosurgery 2015;62:209.
   Google Scholar
• Suzuki T, Wada S, Eguchi H, et al. Cadherin 13 overexpression as an important factor related to the absence of tumour fluorescence in 5-aminolevulinic acid-guided resection of glioma. J Neurosurg 2013;119:1331–9.
   PubMed Web of Science ®Google Scholar
• Kamp MA, Felsberg J, Sadat H, et al. 5-ALA-induced fluorescence behavior of reactive tissue changes following glioblastoma treatment with radiation and chemotherapy. Acta Neurochir (Wien) 2015;157:207–13 (discussion 213–4).
   PubMed Web of Science ®Google Scholar
• Bobek-Billewicz B, Stasik-Pres G, Majchrzak H, Zarudzki L. Differentiation between brain tumour recurrence and radiation injury using perfusion, diffusion-weighted imaging and MR spectroscopy. Folia Neuropathol 2010;48:81–92.
   PubMed Web of Science ®Google Scholar
• Fink JR, Carr RB, Matsusue E, et al. Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma recurrence from posttreatment effects. J Magn Reson Imaging 2012;35:56–63.
   PubMed Web of Science ®Google Scholar
• Hatiboglu MA, Weinberg JS, Suki D, et al. Impact of intraoperative high-field magnetic resonance imaging guidance on glioma surgery: a prospective volumetric analysis. Neurosurgery 2009;64:1073–81 (discussion 1081).
   PubMed Web of Science ®Google Scholar
• Kuhnt D, Becker A, Ganslandt O, Bauer M, Buchfelder M, Nimsky C. Correlation of the extent of tumour volume resection and patient survival in surgery of glioblastoma multiforme with high-field intraoperative MRI guidance. Neuro Oncol 2011;13:1339–48.
   PubMed Web of Science ®Google Scholar
• Eyüpoglu IY, Hore N, Savaskan NE, et al. Improving the extent of malignant glioma resection by dual intraoperative visualization approach. PLoS One 2012;7:e44885.
   Web of Science ®Google Scholar
• Gessler F, Forster MT, Duetzmann S, et al. Combination of intraoperative magnetic resonance imaging and intraoperative fluorescence to enhance the resection of contrast enhancing gliomas. Neurosurgery 2015;77:16–22.
   PubMed Web of Science ®Google Scholar
• Roder C, Bisdas S, Ebner FH, et al. Maximizing the extent of resection and survival benefit of patients in glioblastoma surgery: high-field iMRI versus conventional and 5-ALA-assisted surgery. Eur J Surg Oncol 2014;40:297–304.
   PubMed Web of Science ®Google Scholar